725 related articles for article (PubMed ID: 23490192)
1. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
2. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
[TBL] [Abstract][Full Text] [Related]
6. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
[TBL] [Abstract][Full Text] [Related]
8. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
9. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
10. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
Kuo HK; Sun IT; Chung MY; Chen YH
Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
[TBL] [Abstract][Full Text] [Related]
11. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
Kychenthal A; Dorta P
Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
Mintz-Hittner HA; Kuffel RR
Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
[TBL] [Abstract][Full Text] [Related]
13. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.
Xu Y; Zhang Q; Kang X; Zhu Y; Li J; Chen Y; Zhao P
Acta Ophthalmol; 2013 Jun; 91(4):e304-10. PubMed ID: 23647944
[TBL] [Abstract][Full Text] [Related]
14. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
15. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
16. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
17. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
[TBL] [Abstract][Full Text] [Related]
18. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of retinopathy of prematurity after bevacizumab injection.
Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R
Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394
[TBL] [Abstract][Full Text] [Related]
20. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?
Spandau U; Tomic Z; Ewald U; Larsson E; Akerblom H; Holmström G
Acta Ophthalmol; 2013 Mar; 91(2):170-5. PubMed ID: 22268644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
